glp 1 anesthesia guidelines 2025 Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists New Study Recommends Stopping GLP-1

M.AlmohammedO

(2025) [14] conducted a randomized trial examining liraglutide withdrawal in patients with type 2 diabetes and reported a mean weight regain of 2.4 kg at 24 weeks post-discontinuation, corroborating the rebound trends identified in our subgroup analysis

Front Immunol (2022) 13:967151

The fasting trial showed 15% less rebound eating four hours after the last dose, confirming 4-6 hour duration

Mller TD, Finan B, Bloom SR, DAlessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschp MH

Members also receive support for side-effect management, nutrition as appetite changes, and muscle-preservation strategies to support long-term metabolic health